{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:36:06Z","timestamp":1787002566230,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"46","license":[{"start":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T00:00:00Z","timestamp":1453680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/onc.2015.498","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T06:16:49Z","timestamp":1453702609000},"page":"5963-5976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties"],"prefix":"10.1038","volume":"35","author":[{"given":"A N","family":"Paranjape","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Soundararajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S J","family":"Werden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J H","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Rodriguez-Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Sphyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J T","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S N","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D G","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,25]]},"reference":[{"key":"BFonc2015498_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","volume":"12","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Zhang T, Small EJ, Armstrong AJ . Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 2014; 12: 719\u2013726.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFonc2015498_CR2","first-page":"273","volume":"2","author":"V Parimi","year":"2014","unstructured":"Parimi V, Goyal R, Poropatich K, Yang XJ . Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2014; 2: 273\u2013285.","journal-title":"Am J Clin Exp Urol"},{"key":"BFonc2015498_CR3","doi-asserted-by":"publisher","first-page":"12182","DOI":"10.1073\/pnas.0804700105","volume":"105","author":"Y Niu","year":"2008","unstructured":"Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182\u201312187.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015498_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/emmm.201202367","volume":"5","author":"K Izumi","year":"2013","unstructured":"Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ et al. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2\/CCR2-induced STAT3 activation. EMBO Mol Med 2013; 5: 1383\u20131401.","journal-title":"EMBO Mol Med"},{"key":"BFonc2015498_CR5","doi-asserted-by":"publisher","first-page":"11897","DOI":"10.1158\/0008-5472.CAN-06-2497","volume":"66","author":"JN Davis","year":"2006","unstructured":"Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA et al. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 2006; 66: 11897\u201311906.","journal-title":"Cancer Res"},{"key":"BFonc2015498_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ng1935","volume":"39","author":"SA Tomlins","year":"2007","unstructured":"Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41\u201351.","journal-title":"Nat Genet"},{"key":"BFonc2015498_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3892\/ijo.2014.2529","volume":"45","author":"V Castillo","year":"2014","unstructured":"Castillo V, Valenzuela R, Huidobro C, Contreras HR, Castellon EA . Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer. Int J Oncol 2014; 45: 985\u2013994.","journal-title":"Int J Oncol"},{"key":"BFonc2015498_CR8","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ . Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946\u201310951.","journal-title":"Cancer Res"},{"key":"BFonc2015498_CR9","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1002\/ijc.28561","volume":"134","author":"TW Friedlander","year":"2014","unstructured":"Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 2014; 134: 2284\u20132293.","journal-title":"Int J Cancer"},{"key":"BFonc2015498_CR10","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/sj.onc.1209327","volume":"25","author":"L Patrawala","year":"2006","unstructured":"Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696\u20131708.","journal-title":"Oncogene"},{"key":"BFonc2015498_CR11","first-page":"630","volume":"1846","author":"M Santoni","year":"2014","unstructured":"Santoni M, Conti A, Burattini L, Berardi R, Scarpelli M, Cheng L et al. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 2014; 1846: 630\u2013637.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2015498_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1177\/1535370214538727","volume":"239","author":"P Li","year":"2014","unstructured":"Li P, Wang J, Chu M, Zhang K, Yang R, Gao WQ . Zeb1 promotes androgen independence of prostate cancer via induction of stem cell-like properties. Exp Biol Med (Maywood) 2014; 239: 813\u2013822.","journal-title":"Exp Biol Med (Maywood)"},{"key":"BFonc2015498_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1158\/0008-5472.CAN-11-3004","volume":"72","author":"Y Sun","year":"2012","unstructured":"Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen- deprivation therapy. Cancer Res 2012; 72: 527\u2013536.","journal-title":"Cancer Res"},{"key":"BFonc2015498_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1096\/fj.09-136994","volume":"24","author":"ML Zhu","year":"2010","unstructured":"Zhu ML, Kyprianou N . Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010; 24: 769\u2013777.","journal-title":"FASEB J"},{"key":"BFonc2015498_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.stem.2012.03.009","volume":"10","author":"J Qin","year":"2012","unstructured":"Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR et al. The PSA(-\/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012; 10: 556\u2013569.","journal-title":"Cell Stem Cell"},{"key":"BFonc2015498_CR16","doi-asserted-by":"publisher","first-page":"10069","DOI":"10.1073\/pnas.0703900104","volume":"104","author":"SA Mani","year":"2007","unstructured":"Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 2007; 104: 10069\u201310074.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015498_CR17","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/0008-5472.CAN-12-2962","volume":"73","author":"BG Hollier","year":"2013","unstructured":"Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 2013; 73: 1981\u20131992.","journal-title":"Cancer Res"},{"key":"BFonc2015498_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1186\/1471-2407-14-785","volume":"14","author":"AN Paranjape","year":"2014","unstructured":"Paranjape AN, Balaji SA, Mandal T, Krushik EV, Nagaraj P, Mukherjee G et al. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. BMC Cancer 2014; 14: 785.","journal-title":"BMC Cancer"},{"key":"BFonc2015498_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ncb1998","volume":"11","author":"U Wellner","year":"2009","unstructured":"Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487\u20131495.","journal-title":"Nat Cell Biol"},{"key":"BFonc2015498_CR20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cell.2013.06.005","volume":"154","author":"CL Chaffer","year":"2013","unstructured":"Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61\u201374.","journal-title":"Cell"},{"key":"BFonc2015498_CR21","doi-asserted-by":"publisher","first-page":"36529","DOI":"10.1074\/jbc.M503111200","volume":"280","author":"SM Pulukuri","year":"2005","unstructured":"Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005; 280: 36529\u201336540.","journal-title":"J Biol Chem"},{"key":"BFonc2015498_CR22","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/sj.bjc.6604242","volume":"98","author":"EM Hurt","year":"2008","unstructured":"Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL . CD44+ CD24(-) prostate cells are early cancer progenitor\/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008; 98: 756\u2013765.","journal-title":"Br J Cancer"},{"key":"BFonc2015498_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10911-009-9110-3","volume":"14","author":"BG Hollier","year":"2009","unstructured":"Hollier BG, Evans K, Mani SA . The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009; 14: 29\u201343.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"BFonc2015498_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1078-0432.CCR-11-1867","volume":"18","author":"V Tzelepi","year":"2012","unstructured":"Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012; 18: 666\u2013677.","journal-title":"Clin Cancer Res"},{"key":"BFonc2015498_CR25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/pros.21301","volume":"71","author":"A Aparicio","year":"2011","unstructured":"Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011; 71: 846\u2013856.","journal-title":"Prostate"},{"key":"BFonc2015498_CR26","doi-asserted-by":"publisher","first-page":"15449","DOI":"10.1073\/pnas.1004900107","volume":"107","author":"JH Taube","year":"2010","unstructured":"Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107: 15449\u201315454.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015498_CR27","doi-asserted-by":"publisher","first-page":"e00499","DOI":"10.7554\/eLife.00499","volume":"2","author":"MD Balbas","year":"2013","unstructured":"Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2013; 2: e00499.","journal-title":"eLife"},{"key":"BFonc2015498_CR28","doi-asserted-by":"publisher","first-page":"11399","DOI":"10.18632\/oncotarget.2550","volume":"5","author":"H Tamaki","year":"2014","unstructured":"Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H et al. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Oncotarget 2014; 5: 11399\u201311412.","journal-title":"Oncotarget"},{"key":"BFonc2015498_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/1947601913507951","volume":"4","author":"HK Koul","year":"2013","unstructured":"Koul HK, Pal M, Koul S . Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013; 4: 342\u2013359.","journal-title":"Genes Cancer"},{"key":"BFonc2015498_CR30","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1158\/0008-5472.CAN-12-0254","volume":"72","author":"M Shiota","year":"2012","unstructured":"Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S et al. Clusterin mediates TGF-beta-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res 2012; 72: 5261\u20135272.","journal-title":"Cancer Res"},{"key":"BFonc2015498_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1476-4598-13-55","volume":"13","author":"P Li","year":"2014","unstructured":"Li P, Yang R, Gao WQ . Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer 2014; 13: 55.","journal-title":"Mol Cancer"},{"key":"BFonc2015498_CR32","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/1535-7163.MCT-13-0775","volume":"13","author":"M Marin-Aguilera","year":"2014","unstructured":"Marin-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernandez PL, Pereira MV et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther 2014; 13: 1270\u20131284.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2015498_CR33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pros.21132","volume":"70","author":"D McKeithen","year":"2010","unstructured":"McKeithen D, Graham T, Chung LWK, Odero-Marah V . Snail transcription factor regulates neuroendocrine differentiationin LNCaP prostate cancer cells. Prostate 2010; 70: 982\u2013992.","journal-title":"Prostate"},{"key":"BFonc2015498_CR34","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1158\/0008-5472.CAN-04-3785","volume":"65","author":"WK Kwok","year":"2005","unstructured":"Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65: 5153\u20135162.","journal-title":"Cancer Res"},{"key":"BFonc2015498_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fonc.2014.00370","volume":"4","author":"M Nouri","year":"2014","unstructured":"Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG, Williams ED . Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol 2014; 4: 370.","journal-title":"Front Oncol"},{"key":"BFonc2015498_CR36","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.bbrc.2006.12.077","volume":"353","author":"Y Shida","year":"2007","unstructured":"Shida Y, Igawa T, Hakariya T, Sakai H, Kanetake H . p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion. Biochem Biophys Res Commun 2007; 353: 744\u2013749.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2015498_CR37","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1038\/cddis.2013.165","volume":"4","author":"MR Milone","year":"2013","unstructured":"Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S et al. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis 2013; 4: e641.","journal-title":"Cell Death Dis"},{"key":"BFonc2015498_CR38","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s10495-006-0086-9","volume":"11","author":"M Ricote","year":"2006","unstructured":"Ricote M, Garcia-Tunon I, Fraile B, Fernandez C, Aller P, Paniagua R et al. P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis 2006; 11: 1969\u20131975.","journal-title":"Apoptosis"},{"key":"BFonc2015498_CR39","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/pros.21331","volume":"71","author":"L Gan","year":"2011","unstructured":"Gan L, Wang J, Xu H, Yang X . Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38\/p53\/p21 signaling. Prostate 2011; 71: 1158\u20131166.","journal-title":"Prostate"},{"key":"BFonc2015498_CR40","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/onc.2008.476","volume":"28","author":"L Khandrika","year":"2009","unstructured":"Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R et al. Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 2009; 28: 1248\u20131260.","journal-title":"Oncogene"},{"key":"BFonc2015498_CR41","doi-asserted-by":"publisher","first-page":"11153","DOI":"10.1074\/jbc.M113.540237","volume":"289","author":"B Ma","year":"2014","unstructured":"Ma B, Wells A . The mitogen-activated protein (MAP) kinases p38 and extracellular signal-regulated kinase (ERK) are involved in hepatocyte-mediated phenotypic switching in prostate cancer cells. J Bol Chem 2014; 289: 11153\u201311161.","journal-title":"J Bol Chem"},{"key":"BFonc2015498_CR42","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/BOR.0b013e3283378e6f","volume":"22","author":"S Cohen","year":"2010","unstructured":"Cohen S, Fleischmann R . Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010; 22: 330\u2013335.","journal-title":"Curr Opin Rheumatol"},{"key":"BFonc2015498_CR43","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/thoraxjnl-2012-202744","volume":"68","author":"W MacNee","year":"2013","unstructured":"MacNee W, Allan RJ, Jones I, De Salvo MC, Tan LF . Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013; 68: 738\u2013745.","journal-title":"Thorax"},{"key":"BFonc2015498_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.110.971986","volume":"123","author":"J Cheriyan","year":"2011","unstructured":"Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, Maki-Petaja KM et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 2011; 123: 515\u2013523.","journal-title":"Circulation"},{"key":"BFonc2015498_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1042\/bj3510095","volume":"351","author":"SP Davies","year":"2000","unstructured":"Davies SP, Reddy H, Caivano M, Cohen P . Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95\u2013105.","journal-title":"Biochem J"},{"key":"BFonc2015498_CR46","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187\u20131197.","journal-title":"N Engl J Med"},{"key":"BFonc2015498_CR47","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/onc.2014.245","volume":"34","author":"TR Sarkar","year":"2015","unstructured":"Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Pena EQ, Taube JH et al. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 2015; 34: 2958\u20132967.","journal-title":"Oncogene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2015498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2015498","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2015498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:58:59Z","timestamp":1684457939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2015498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,25]]},"references-count":47,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFonc2015498"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.498","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,25]]},"assertion":[{"value":"29 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ANP, RS, SJW, NS and SAM are inventors of a patent application in part based on findings described in this manuscript. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}